secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2022-08-30T23:59:59+00:00
Accession:  0001558370-22-014068
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn appoints Ryan Dunlap as director, effective Aug 25, 2022
----------------------------------------------------------------

- Ryan Dunlap appointed as director, filling vacancy from Nader Pourhassan's Jan 2022 resignation.
- Expected to join the Audit Committee; Dunlap has over 25 years of finance and operations leadership.
- Currently CFO at Gurobi Optimization; prior CFO at a publicly traded biotech/pharma sales company.
- Compensation consistent with non-employee director policies; includes cash retainers and stock options.
- No family relationships or transactions requiring disclosure under Item 404(a) of Regulation S-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000155837022014068/0001558370-22-014068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000155837022014068/cydy-20220824x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-014068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer